PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will showcase its strategy and pipeline to the investment community next week, with executives slated to appear at three major healthcare conferences in Miami and New York.
The company will participate in Citi’s 2025 Global Healthcare Conference on Tuesday, Dec. 2, followed by a fireside chat the same day at the 8th Annual Evercore Healthcare Conference. Harmony leadership will then take part in a second fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3. Webcasts of both discussions will be available on the company’s investor relations website.
The meetings come as Harmony continues to expand its presence in treatments for rare neurological diseases. Since its founding by Paragon Biosciences in 2017, the Plymouth Meeting–based firm has focused on developing and commercializing therapies for patients with limited or no existing options, underscoring what it describes as a mission rooted in both scientific innovation and patient-centered values.
Harmony says its approach blends emerging neuroscience, targeted development programs, and close engagement with patient communities. The company highlighted its ongoing commitment to advancing new therapies and fostering a culture that prioritizes empathy, scientific rigor, and support for those living with rare conditions.
Investors tuning in next week are expected to receive updates on the company’s development priorities, commercial performance, and long-term strategic outlook.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.